Mizuho analyst Uy Ear raised the firm’s price target on uniQure (QURE) to $60 from $30 and keeps an Outperform rating on the shares. The firm views the Phase 1/2 trial results of AMT-130 in Huntington’s Disease as “highly positive.” The results should support potential approval, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure price target raised to $65 from $30 at Wells Fargo
- UniQure (QURE) Stock Jumps 248% on Huntington’s Trial Results. Analysts Raise Price Targets
- uniQure Announces Positive Results for Huntington’s Study
- uniQure Secures $175 Million Loan Amendment
- uniQure’s Promising Advancements in Huntington’s Disease Treatment and Strong Financial Position Justify Buy Rating